PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary

January 26, 2015 7:42 PM

4 0

(Reuters) - Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus.

EnvisionRx said Gilead's Sovaldi and its newer two-drug combination pill Harvoni would be available on its formulary, with other hepatitis C drugs, such as AbbVie's Viekira Pak, allowed only as an exception in some cases.

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...